Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.
about
Selective estrogen receptor modulators (SERMs) for uterine leiomyomasLasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisEffects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceThe effect of long-term hormonal treatment on voiding patterns during filling cystometry and on urethral histology in a postpartum, ovariectomized female rat.The potential of hormones and selective oestrogen receptor modulators in preventing voiding dysfunction in ratsAnti-breast cancer potential of SS5020, a novel benzopyran antiestrogenNeoplasms of the reproductive tract: the role of hormone exposure.Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.Urogenital effects of selective estrogen receptor modulators: a systematic review.Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells.Effects of birth trauma and estrogen on urethral elastic fibers and elastin expressionRelationship between dietary phytoestrogens and development of urinary incontinence in midlife women.Effect of extended-term estrogen on voiding in a postpartum ovariectomized rat model.Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse.Estrogen-related genome-based expression profiling study of uterosacral ligaments in women with pelvic organ prolapse.Effects of tamoxifen on urinary incontinence: Case report and review of literature.Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions.Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety.Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.Stimulatory adrenocortical effects of a selective estrogen receptor modulator in ovariectomized female macaques.The long-term effect of raloxifene on the genitourinary tract.The effect of raloxifene, a SERM, on extracellular matrix protein expression of pelvic fibroblasts.Selective estrogen receptor modulators (SERMS).
P2860
Q24198863-99BF0D9F-FAA3-4FA1-AB34-74C6483C3400Q28258418-1437C79F-7F9C-4D5E-B6E9-0A0DEBDE2566Q30380010-AFBA7FA1-A8ED-4BEA-BFAA-1AB6128F1CDFQ34031819-3FB71EC9-C3D6-4B32-82BC-2E4260DC8FD1Q34358011-9E95D92B-FD76-49A0-88A0-8163CB6B48DCQ34446978-EE4A6CFD-3998-4548-8301-B41B7EBC1A6AQ35757570-A3838DCD-2CE6-4EC7-9918-6B72340D9012Q35775369-A85FC15B-1B08-44A3-A6C8-013E2A9017C6Q36359543-ED358409-176D-41AD-82F8-B2363EDE4FD7Q36509457-214833B0-BE2C-4969-B8B4-9FCC563B5A5FQ36541324-05052E22-0E6B-4409-AEC2-95E5CFC4C078Q36598646-D9B98570-EC64-4F45-A8C3-3F57F963C44FQ36710410-0CFF6FF1-0971-44A5-880B-461012CD907CQ37698607-20B50334-5A2B-4DBE-B3CD-CADF8BE1D7FBQ38039848-B68A025C-0C79-4E0B-8D82-4A154D8DF3F3Q38450146-7D99E5D9-41D4-446F-BD47-80F096FBB78AQ41523627-D06778FF-C3E2-4673-B0DA-A561E7D4E2D5Q43194866-50AB8E89-B6AD-4016-BA65-D3D20EDCB225Q43267067-E348A2AA-90E0-4D51-B6A1-90AE8C977EF4Q46417845-C9EB9DAA-3B95-499E-9758-DADEE4501EE9Q48824369-1102F408-CCE1-48E9-BAB4-D7E03D559C33Q53193367-A5297B0A-AEB4-4996-BC42-6A4880519A94Q54347765-F3D98144-FC9E-4FAA-A753-7437FF4006F3Q55042739-11B1EF93-82DF-417B-B884-FE45A4D64550
P2860
Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Adverse events that are associ ...... osteoporosis treatment study.
@en
Adverse events that are associ ...... osteoporosis treatment study.
@nl
type
label
Adverse events that are associ ...... osteoporosis treatment study.
@en
Adverse events that are associ ...... osteoporosis treatment study.
@nl
prefLabel
Adverse events that are associ ...... osteoporosis treatment study.
@en
Adverse events that are associ ...... osteoporosis treatment study.
@nl
P356
P1476
Adverse events that are associ ...... osteoporosis treatment study.
@en
P2093
Nayan Nanavati
Steven R Goldstein
P304
P356
10.1067/MOB.2002.123938
P407
P577
2002-09-01T00:00:00Z